Stuart Thomson
- Oncology top 2%
- Peptidase Inhibition and Analysis 4
- HER2/EGFR in Cancer Research 4
- Cancer Cells and Metastasis 3
- Cancer Research top 5%
- Molecular Biology top 5%
- Ubiquitin and proteasome pathways 9
- Genomics and Chromatin Dynamics 4
- Protein Kinase Regulation and GTPase Signaling 3
-
- Lung Cancer Treatments and Mutations 6
- Cell Biology top 5%
-
- Micro and Nano Robotics 5
- Co-authors
- John D. HaleyLouis C. MahadevanAlison L. ClaytonFilippo PettiNeil W. GibsonKenneth K. IwataElizabeth BuckDavid Epstein
- Journals
- Cancer Research (4 papers)Clinical & Experimental Metastasis (4 papers)Molecular Cancer Therapeutics (3 papers)
- Partner nations
- United KingdomUnited StatesGermany
In The Last Decade
Stuart Thomson
54 papers receiving 3.7k citations
Hit Papers
Peers
Comparison fields: 5 of 150
- Oncology 1.2k
- Cancer Research 511
- Molecular Biology 2.1k
- Pulmonary and Respiratory Medicine 696
- Cell Biology 313
Countries citing papers authored by Stuart Thomson
This map shows the geographic impact of Stuart Thomson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stuart Thomson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stuart Thomson more than expected).
Fields of papers citing papers by Stuart Thomson
This network shows the impact of papers produced by Stuart Thomson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stuart Thomson. The network helps show where Stuart Thomson may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Stuart Thomson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 2 | |
| 2 | 2023 | 6 | |
| 3 | 2017 | 15 | |
| 4 | 2014 | 39 | |
| 5 | 2010 | 178 | |
| 6 | 2008 | 164 | |
| 7 | 2008 | 156 | |
| 8 | The EGFR antagonist, erlotinib, combined with a small molecule inhibitor of IGF-1R acts synergistically to inhibit proliferation and induce apoptosis in ovarian and HNSCC cells | 2007 | 3 |
| 9 | Differential effects for small molecule versus antibody inhibitors of EGFR: Erlotinib, but not the neutralizing antibody C225, achieves inhibition of the EGFR-HER3-Akt signaling cascade | 2007 | 1 |
| 10 | 2007 | 11 | |
| 11 | 2005 | 177 | |
| 12 | 2004 | 11 | |
| 13 | 2003 | 64 | |
| 14 | 2002 | 17 | |
| 15 | 2001 | 176 | |
| 16 | 2001 | 67 | |
| 17 | 1999 | 380 | |
| 18 | 1995 | 86 | |
| 19 | 1995 | 18 | |
| 20 | 1993 | 16 |
About Stuart Thomson
Stuart Thomson is a scholar working on Oncology, Aging and Condensed Matter Physics, having authored 55 papers that have together received 3.7k indexed citations. Recurring topics across this work include Ubiquitin and proteasome pathways (9 papers), Lung Cancer Treatments and Mutations (6 papers), Micro and Nano Robotics (5 papers), Peptidase Inhibition and Analysis (4 papers), HER2/EGFR in Cancer Research (4 papers), Genomics and Chromatin Dynamics (4 papers), Cancer Cells and Metastasis (3 papers) and Protein Kinase Regulation and GTPase Signaling (3 papers). The work is most often cited by research in Oncology (1.2k citations), Cancer Research (511 citations) and Molecular Biology (2.1k citations). Stuart Thomson has collaborated with scholars based in United Kingdom, United States and Germany. Frequent co-authors include John D. Haley, Louis C. Mahadevan, Alison L. Clayton, Filippo Petti, Neil W. Gibson, Kenneth K. Iwata, Elizabeth Buck, David Epstein, Eric Brown and Graeme Griffin. Their work appears in journals such as Cancer Research, Clinical & Experimental Metastasis, Molecular Cancer Therapeutics, Molecular Cell and Clinical Biochemistry.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.